studies

mBC - Triple negative (TNBC) - 1st Line (L1), atezolizumab plus nab-paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-130 (all population), 2018 0.86 [0.72; 1.02] IMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94] 0.81[0.68; 0.96]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018224%1,271lownot evaluable PFS (extension)detailed resultsIMpassion-130 (all population), 2018 0.80 [0.69; 0.92] IMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80] 0.72[0.57; 0.91]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018265%1,271lownot evaluable progression or deaths (PFS)detailed resultsIMpassion-130 (all population), 2018 0.80 [0.69; 0.92] IMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78] 0.72[0.56; 0.92]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018270%1,271lownot evaluable DORdetailed resultsIMpassion-130 (all population), 2018 0.78 [0.63; 0.97] IMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85] 0.71[0.55; 0.91]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018236%369lownot evaluable objective responses (ORR)detailed resultsIMpassion-130 (all population), 2018 1.52 [1.17; 1.98] IMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98] 1.64[1.31; 2.05]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 201821%1,271lownot evaluable AE (any grade)detailed resultsIMpassion-130 (all population), 2018 3.15 [0.85; 11.73] 3.15[0.85; 11.73]IMpassion-130 (all population), 201810%890NAnot evaluable AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.31 [1.00; 1.70] 1.31[1.00; 1.70]IMpassion-130 (all population), 201810%890NAnot evaluable AE leading to death (grade 5)detailed resultsIMpassion-130 (all population), 2018 1.94 [0.48; 7.81] 1.94[0.48; 7.81]IMpassion-130 (all population), 201810%890NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpassion-130 (all population), 2018 2.24 [1.46; 3.43] 2.24[1.46; 3.43]IMpassion-130 (all population), 201810%890NAnot evaluable SAE (any grade)detailed resultsIMpassion-130 (all population), 2018 1.33 [0.96; 1.84] 1.33[0.96; 1.84]IMpassion-130 (all population), 201810%890NAnot evaluable STRAE (any grade)detailed resultsIMpassion-130 (all population), 2018 1.82 [1.16; 2.87] 1.82[1.16; 2.87]IMpassion-130 (all population), 201810%890NAnot evaluable TRAE (any grade)detailed resultsIMpassion-130 (all population), 2018 1.80 [0.96; 3.39] 1.80[0.96; 3.39]IMpassion-130 (all population), 201810%890NAnot evaluable TRAE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.52 [1.15; 2.01] 1.52[1.15; 2.01]IMpassion-130 (all population), 201810%890NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpassion-130 (all population), 2018 2.91 [0.30; 28.05] 2.91[0.30; 28.05]IMpassion-130 (all population), 201810%890NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.93[0.17; 21.40]IMpassion-130 (all population), 201810%890NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Adrenal insufficiency AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.93[0.17; 21.40]IMpassion-130 (all population), 201810%890NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.04 [0.48; 2.24] 1.04[0.48; 2.24]IMpassion-130 (all population), 201810%890NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.72 [0.16; 3.24] 0.72[0.16; 3.24]IMpassion-130 (all population), 201810%890NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 2.92 [0.59; 14.54] 2.92[0.59; 14.54]IMpassion-130 (all population), 201810%890NAnot evaluable Cardiomyopathy AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Chills AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 2.91 [0.30; 28.05] 2.91[0.30; 28.05]IMpassion-130 (all population), 201810%890NAnot evaluable Cough AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.19; 4.80] 0.96[0.19; 4.80]IMpassion-130 (all population), 201810%890NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.85 [0.33; 2.24] 0.85[0.33; 2.24]IMpassion-130 (all population), 201810%890NAnot evaluable Dizziness AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Dysphonia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.19; 4.80] 0.96[0.19; 4.80]IMpassion-130 (all population), 201810%890NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.10 [0.54; 2.22] 1.10[0.54; 2.22]IMpassion-130 (all population), 201810%890NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.48 [0.09; 2.63] 0.48[0.09; 2.63]IMpassion-130 (all population), 201810%890NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.35 [0.11; 1.09] 0.35[0.11; 1.09]IMpassion-130 (all population), 201810%890NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.38; 2.45] 0.96[0.38; 2.45]IMpassion-130 (all population), 201810%890NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.55 [0.50; 4.79] 1.55[0.50; 4.79]IMpassion-130 (all population), 201810%890NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.55 [0.50; 4.79] 1.55[0.50; 4.79]IMpassion-130 (all population), 201810%890NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.94 [0.35; 10.63] 1.94[0.35; 10.63]IMpassion-130 (all population), 201810%890NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.64 [0.11; 3.86] 0.64[0.11; 3.86]IMpassion-130 (all population), 201810%890NAnot evaluable Myopathy AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.60 [0.19; 1.84] 0.60[0.19; 1.84]IMpassion-130 (all population), 201810%890NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.02 [0.63; 1.64] 1.02[0.63; 1.64]IMpassion-130 (all population), 201810%890NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.93[0.17; 21.40]IMpassion-130 (all population), 201810%890NAnot evaluable Pericarditis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 2.07 [1.03; 4.17] 2.07[1.03; 4.17]IMpassion-130 (all population), 201810%890NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.16 [0.02; 1.33] 0.16[0.02; 1.33]IMpassion-130 (all population), 201810%890NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 3.27 [0.89; 11.95] 3.27[0.89; 11.95]IMpassion-130 (all population), 201810%890NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 3.87 [0.17; 86.09] 3.87[0.17; 86.09]IMpassion-130 (all population), 201810%890NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 5.82 [0.29; 116.53] 5.82[0.29; 116.53]IMpassion-130 (all population), 201810%890NAnot evaluable Rash AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.14; 6.88] 0.96[0.14; 6.88]IMpassion-130 (all population), 201810%890NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.16 [0.01; 3.20] 0.16[0.01; 3.20]IMpassion-130 (all population), 201810%890NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.93[0.17; 21.40]IMpassion-130 (all population), 201810%890NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.77 [0.21; 2.89] 0.77[0.21; 2.89]IMpassion-130 (all population), 201810%890NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 5.82 [0.29; 116.53] 5.82[0.29; 116.53]IMpassion-130 (all population), 201810%890NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-01 01:29 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 269,60,143 - treatments: 1281

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons